Liping Luo
Shenzhen, 518038, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Autosomal dominant thrombocytopenia caused by a heterozygous CYCS variant: a new family and literature review.
Journal: Journal of thrombosis and haemostasis : JTH
Published: April 15, 2026
Infection-Triggered Complex Coagulopathy With Lupus Anticoagulant, Heparinoid Inhibitors, and ITP-Like Thrombocytopenia Associated With Bleeding: Successful IVIG Treatment Monitored by Thromboelastography.
Journal: International journal of laboratory hematology
Published: March 10, 2026
Detailed Immunological Characterization of Platelet Recovery in Refractory Pediatric ITP: A Case Report.
Journal: International journal of laboratory hematology
Published: October 08, 2025
Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models.
Journal: Vaccine
Published: May 12, 2025
Management of infection and ocular complications in pediatric SJS/TEN-like acute graft-versus-host disease: a clinical case study and literature review.
Journal: Frontiers in immunology
Published: March 05, 2025
An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease.
Journal: Vaccines
Published: November 23, 2024
Biofluid-Derived Exosomal LncRNAs: Their Potential in Obesity and Related Comorbidities.
Journal: Biology
Published: November 05, 2024
A Dataset for Investigations of Amine-Impregnated Solid Adsorbent for Direct Air Capture.
Journal: Scientific data
Published: August 09, 2024
Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity.
Journal: Frontiers in immunology
Published: June 26, 2024
Pseudomonas aeruginosa exotoxin A as a novel allergen induced Non-TH2 inflammation in a murine model of steroid-insensitive asthma.
Journal: Heliyon
Published: April 16, 2024
Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
Journal: Frontiers in immunology
Published: April 07, 2024
Last Updated: 09/26/2026